EU Health Technology Assessment Brief

Headline

European Commission publishes delegated acts establishing regulatory pathways for well-established medical device technologies under the EU MDR

Executive Summary

The European Commission published delegated acts on June 29, 2026 defining the regulatory treatment of well-established technologies under the EU Medical Devices Regulation. The acts create differentiated conformity assessment pathways for device categories that meet the well-established technology criteria.

Bottom Line

The delegated acts introduce a binding, differentiated regulatory pathway for well-established medical device technologies within the EU MDR framework. Manufacturers whose devices qualify face a concrete decision point: assess portfolio eligibility, map existing technical documentation against the new clinical evidence thresholds, and determine whether the revised conformity assessment route applies to active or planned submissions. Notified bodies must update their procedural scope to accommodate the new submission category. The acts carry the force of binding secondary legislation from their entry into force date.

Key Regulatory Signals

• New Conformity Assessment Pathway Opens: Manufacturers of devices qualifying as well-established technologies gain access to a modified conformity assessment route. Affected manufacturers must determine whether their device portfolio meets the qualifying criteria and initiate reclassification or pathway-selection procedures accordingly.
• Notified Bodies Face Revised Scope: The delegated acts alter the scope of notified body involvement for qualifying device categories. Notified bodies operating under EU MDR designation must update their internal procedures to reflect the revised assessment requirements for well-established technology submissions.
• Clinical Evidence Standards Adjusted for Qualifying Devices: The acts address clinical evidence requirements for well-established technologies, where reliance on established clinical data may substitute for new clinical investigations. Manufacturers must map existing technical documentation against the new evidentiary thresholds to confirm compliance.
• Market Access Timeline Implications: Devices that qualify under the new framework may reach the EU market under a revised procedural timeline. Manufacturers with products in active conformity assessment should assess whether transitioning to the new pathway affects their current certification schedules.

Regulatory Delta

- The EU MDR entered full application in May 2021 but has not previously included a delegated act carving out a well-established technology pathway. This publication is a structural addition to the conformity assessment architecture.

- The delegated acts move beyond interpretive guidance into binding secondary legislation, creating enforceable obligations and entitlements that did not exist under prior Commission implementing measures.

- The European Parliament and Council retain scrutiny rights over delegated acts under the MDR empowerment provisions. As of the release date, the publication record reflects no objection period outcome.

Materiality Classification

HIGH — Binding delegated acts under the EU MDR create enforceable conformity assessment pathways applicable across the medical device manufacturing sector, requiring manufacturers and notified bodies to assess and adjust procedures beyond the named release.

Intelligence Outlook

Monitor the European Commission's DG SANTE and the Official Journal of the European Union for the full text of the delegated acts, their entry into force dates, and any European Parliament or Council objection within the scrutiny period.